Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevanceMaria Secrier, Rebecca C. Fitzgerald, Tim Underwood et al.|Nature Genetics|2016Cited by 439
Identification of Subtypes of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome DataSriganesh Jammula, Vijayendran Sujendran, Annalise Katz‐Summercorn et al.|Gastroenterology|2020Cited by 110
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinomaFergus Noble, Jamie Kelly, Megan Lloyd et al.|British journal of surgery|2017Cited by 108
Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent CohortsTarek Sawas, Richard J.E. Skipworth, Sarah Killcoyne et al.|Gastroenterology|2018Cited by 91
Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinomaThanos P. Mourikis, Shaun R. Preston, Lorena Benedetti et al.|Nature Communications|2019Cited by 49